Other languages Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Market Closed - London S.E. Other stock markets 11:35:30 2024-05-17 am EDT			5-day change	1st Jan Change
3.25 ^GBX	-2.99%		+3.17%	+30.00%

May. 07	Abingdon Health buys IVDeology Holdings	AN
May. 07	Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abingdon Health buys IVDeology Holdings	May. 07
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	May. 07
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	Apr. 03
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	Mar. 27
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	Mar. 27
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	Mar. 27
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	Mar. 27
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	Mar. 27
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 27
Allergy Therapeutics starts dosing patients in peanut allergy trial	Mar. 12
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	Mar. 12
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	Mar. 11
Allergy Therapeutics forecasts revenue drop but trials going well	Feb. 14
Alliance Pharma appoints chair; FireAngel sales down	Feb. 05
Scancell's Chief Development Officer to Step Down	Feb. 05
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	Jan. 30
Allergy Therapeutics amends facility, plans warrant issue	Dec. 27
Allergy Therapeutics Agrees Amendment to Loan Facility	Dec. 27
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	Dec. 15
Allergy Therapeutics' Allergic Rhinoconjunctivitis Treatment Returns Positive Data in Late-stage Trial	Dec. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Other languages

Filters